Immtech Announces Ongoing Efficacy Data of Trypanosomiasis Trial

Immtech International has said that test results from patients enrolled in the Phase IIb clinical trial using DB289 for the oral treatment of Trypanosomiasis confirm that all patients tested remained clear of the African sleeping sickness parasite three months after concluding treatment.

The 30 patients enrolled in the Phase IIb extended-dosage trial received DB289 twice a day for 10 days and all had cleared the parasite in the initial treatment period. Of the 30 original patients, 87 percent returned to the study sites for follow-up testing at three months, a percentage that is considered acceptable for validating test results.

The three month confirmation is the primary endpoint in this clinical trial; patients will continue to be monitored at six, nine and 12 months post treatment.